ArticleCurrent treatment options in oncology2015
Clinical Relevance of Androgen Receptor Splice Variants in Castration-Resistant Prostate Cancer.
Article in Current treatment options in oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 30 citations in OpenAlex.
- Article
- Sex Differences in Taxane Toxicities.Cancers · 2022Review
- Identification of AR-V7 downstream genes commonly targeted by AR/AR-V7 and specifically targeted by AR-V7 in castration resistant prostate cancer.Translational oncology · 2021Article
- Androgen receptor variants: RNA-based mechanisms and therapeutic targets.Human molecular genetics · 2020Review
- Germline HOXB13 mutations p.G84E and p.R217C do not confer an increased breast cancer risk.Scientific reports · 2020Article
- Article
- Diverse AR-V7 cistromes in castration-resistant prostate cancer are governed by HoxB13.Proceedings of the National Academy of Sciences of the United States of America · 2018Article
- Androgen Signaling in Prostate Cancer.Cold Spring Harbor perspectives in medicine · 2017Review
- Prognostic and predictive biomarkers in prostate cancer: latest evidence and clinical implications.Therapeutic advances in medical oncology · 2017Review
- Review
- Proteomics analyses of prostate cancer cells reveal cellular pathways associated with androgen resistance.Proteomics · 2017Article
- Androgen receptor variation affects prostate cancer progression and drug resistance.Pharmacological research · 2016Review
- Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker With Outcomes and Survival in Castration-Resistant Prostate Cancer.JAMA oncology · 2016Article
- New drugs in prostate cancer.Prostate international · 2016Review
- Gene expression profiling and DNA methylation analyses of CTCs.Molecular oncology · 2016Review
- Galeterone for the treatment of advanced prostate cancer: the evidence to date.Drug design, development and therapy · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
opinion statementMetastatic castration-resistant prostate cancer (mCRPC) currently benefits from a wealth of treatment options, yet still remains lethal in the vast majority of patients. It is becoming increasingly understood that this disease entity continues to evolve over time, acquiring additional and diverse resistance mechanisms with each subsequent therapy used. This dynamic relationship between treatment pressure and disease resistance can be challenging for the managing clinician. The recent discovery of alternate splice variants of the androgen receptor (AR) is one potential mechanism of escape in mCRPC, and recognizing this resistance mechanism might be important for optimal treatment selection for our patients. AR-V7 appears to be the most relevant AR splice variant, and early clinical data suggest that it is a negative prognostic marker in mCRPC. Emerging evidence also suggests that detection of AR-V7 may be associated with resistance to novel hormonal therapy (abiraterone and enzalutamide) but may be compatible with sensitivity to taxane chemotherapy (docetaxel and cabazitaxel). Adding to this complexity is the observation that AR-V7 is a dynamic marker whose status may change across time and depending on selective pressures induced by different therapies. Finally, it is possible that AR-V7 may represent a therapeutic target in mCRPC if drugs can be designed that degrade or inhibit AR splice variants or block their transcriptional activity. Several such agents (including galeterone, EPI-506, and bromodomain/BET inhibitors) are now in clinical development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.